Abstract | BACKGROUND: METHODS: RESULTS: The cure rate in the intention-to-treat analysis was 78% for the fleroxacin- rifampicin group (68 patients) and 75% for the standard therapy group (59 patients; 47 received flucloxacillin, and 12 received vancomycin); in the population of clinically evaluable patients (n=119), the cure rate was 82% and 80%, respectively; and in the population of microbiologically evaluable patients (n=103), the cure rate was 86% and 84%, respectively. Clinical and bacteriological failures after S. aureus infections were documented in similar proportions of patients. The median length of hospital stay after study entry was 12 days in the fleroxacin- rifampicin group, compared with 23 days in the standard treatment group (P=.006). More adverse events probably related to the study drug were reported in the fleroxacin- rifampicin group than in the standard therapy group (15 of 68 vs. 5 of 59 patients; P=.05). CONCLUSIONS:
|
Authors | Jacques Schrenzel, Stephan Harbarth, Gérard Schockmel, Daniel Genné, Thomas Bregenzer, Ursula Flueckiger, Christiane Petignat, Frédérique Jacobs, Patrick Francioli, Werner Zimmerli, Daniel P Lew, Swiss Staphylococcal Study Group |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 39
Issue 9
Pg. 1285-92
(Nov 01 2004)
ISSN: 1537-6591 [Electronic] United States |
PMID | 15494904
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Floxacillin
- Vancomycin
- Fleroxacin
- Rifampin
|
Topics |
- Administration, Oral
- Adult
- Aged
- Bacteremia
(drug therapy)
- Catheters, Indwelling
(microbiology)
- Drug Therapy, Combination
- Female
- Fleroxacin
(administration & dosage, adverse effects, therapeutic use)
- Floxacillin
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Male
- Methicillin Resistance
(drug effects)
- Middle Aged
- Prospective Studies
- Rifampin
(administration & dosage, adverse effects, therapeutic use)
- Safety
- Staphylococcal Infections
(diagnosis, drug therapy, metabolism)
- Staphylococcus
(drug effects, isolation & purification)
- Staphylococcus aureus
(drug effects, isolation & purification)
- Treatment Outcome
- Vancomycin
(administration & dosage, adverse effects, therapeutic use)
|